Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2014 - 2026)

Aclaris Therapeutics' Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $198.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.32% year-over-year to $198.7 million; the TTM figure through Mar 2026 stood at $723.9 million (down 4.99% YoY), while the FY2025 annual figure was $160.5 million, down 27.17% from the prior year.
• Liabilities and Shareholders Equity was $198.7 million for Q1 2026 at Aclaris Therapeutics, up from $160.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $278.0 million in Q2 2022 to a low of $160.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $209.9 million across 5 years, with a median of $198.7 million in 2026.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 40.35% in 2022, then tumbled 31.65% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $254.6 million in 2022, then dropped by 22.46% to $197.4 million in 2023, then advanced by 11.61% to $220.3 million in 2024, then dropped by 27.17% to $160.5 million in 2025, then increased by 23.84% to $198.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $198.7 million (Q1 2026), $160.5 million (Q4 2025), and $175.5 million (Q3 2025), per Business Quant data.